Ask Our Experts - Intertek Pharmaceutical Services

Ask Our Experts! - Contact our experts directly with your technical and commercial questions concerning COVID-19 vaccine, therapeutic or diagnostic development support

Mark Parry, Technical Director
Mark has nearly 20 years’ experience working within the pharmaceutical analysis and formulation development industry, with a particular focus on OINDPs. Mostly working in the pre-approval stages, Mark’s background includes extensive experience with product and formulation development for novel and generic products, as well as method development and validation, stability studies, pharmaceutical development activities, and clinical trial manufacturing for a wide range of clients.

Ashleigh Wake, Business Development Director
Ashleigh has held technical and operational management roles in Zeneca, AstraZeneca and Syngenta before joining Intertek. She has a 20 year career as an operational / technical team leader and study director and has specialized in the delivery of GXP studies on biopharma structure, physiochemical and biological activity. She is currently responsible for strategic growth and business development at Intertek’ centre of excellence for biologics characterisation in the UK.

John Todd, Business Development Director
John has held commercial and management roles in several technology companies. He joined Intertek in 2015 and has been responsible for business development, account management, and stewardship of new and existing partnerships. He routinely works with global companies to design tailored outsourcing contracts to meet their technical and commercial needs and has presented at conferences on outsourcing models for the biopharma sector.
WEBINAR: Webinar Design Verification Testing of Metered Dose Inhalers
PRESENTATION: Top Considerations for Inhaled Biologic Development
WHITE PAPER: Best Practice for Pharma Remote Audits
ARTICLE: Biomarker Development & Validation
WHITE PAPER: Mitigating Risks in Pharmaceutical Batch Release
WEBINAR: Hi-Res Accurate MS Method for Nitrosamine Impurities
REPORT:Peptide Therapeutics, Designing a Strategic QC Program
ARTICLE:Biophysical Characterisation of Biosimilars
WEBINAR: Glycosylation Site Specific Approaches for Antibody Therapies
eBOOK: Contingency Outsourcing Solutions
Access our comprehensive Digital Resource Library
COVID-19 VACCINE AND THERAPEUTIC TESTING AND DEVELOPMENT SUPPORT
NEW: Immediate Question? ASK OUR EXPERTS NOW
FACTSHEET: COVID-19 Vaccine and Therapeutic Testing and Development Outsourcing Solutions
ARTICLE: Repurposing Vaccines for Intranasal Development
WEBINAR: Quality Control Strategy for Vaccine Development
WEBINAR: Repurposing Products for Inhaled Delivery - Rapid Response Strategies